BY13 is a potent SRC‑3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer. BY13 could significantly inhibit the growth of drug-resistant breast tumors without observed toxicity in mice. Mechanism studies indicated that the degradation ability of these SRC-3 PROTAC degraders is ubiquitin proteasome system (UPS) pathway-dependent. Moreover, BY13 displays a highly selective blocking effect on the ER signaling pathway over that of the androgen receptor. This proof-of-concept study firmly confirms that SRC-3 is a promising therapeutic target for breast cancer treatment and highlights BY13 as a lead compound for developing novel therapeutics to overcome endocrine resistance in breast cancer.
MedKoo Cat#: 128984
Name: BY13
CAS#: N/A
Chemical Formula: C35H41N9O4
Exact Mass: 651.3282
Molecular Weight: 651.77
Elemental Analysis: C, 64.50; H, 6.34; N, 19.34; O, 9.82
The following data is based on the product molecular weight 651.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |